Nakagawa Noriharu, Yamano Ruiko, Kajikawa Sayaka, Kondo Yukio, Okumura Hirokazu
Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan.
Leuk Res Rep. 2022 May 30;17:100331. doi: 10.1016/j.lrr.2022.100331. eCollection 2022.
The optimal therapy for relapsed primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) remains unclear. We herein report a case of relapsed primary DLBCL of the CNS complicated with primary biliary cholangitis, cirrhosis, and pancytopenia that was successfully treated with bridging therapy with tirabrutinib before autologous hematopoietic stem cell transplantation (ASCT). Tirabrutinib is well tolerated and effective for relapsed primary DLBCL of the CNS with comorbidities, including cirrhosis and pancytopenia. Tirabrutinib is a promising option as bridging therapy before ASCT.
中枢神经系统（CNS）原发性弥漫性大B细胞淋巴瘤（DLBCL）复发后的最佳治疗方案仍不明确。我们在此报告1例CNS原发性DLBCL复发患者，该患者合并原发性胆汁性胆管炎、肝硬化和全血细胞减少，在自体造血干细胞移植（ASCT）前接受了替拉鲁替尼桥接治疗，并获得成功。替拉鲁替尼耐受性良好，对合并肝硬化和全血细胞减少等并发症的CNS原发性DLBCL复发有效。替拉鲁替尼作为ASCT前的桥接治疗是一个有前景的选择。
